Islet	0	5	B-Tissue
endothelial	6	17	I-Tissue
activation	18	28	O
and	29	32	O
oxidative	33	42	O
stress	43	49	O
gene	50	54	O
expression	55	65	O
is	66	68	O
reduced	69	76	O
by	77	79	O
IL	80	82	B-Drug_or_compound
-	82	83	I-Drug_or_compound
1Ra	83	86	I-Drug_or_compound
treatment	87	96	O
in	97	99	O
the	100	103	O
type	104	108	O
2	109	110	O
diabetic	111	119	O
GK	120	122	B-Organism
rat	123	126	I-Organism
.	126	127	O

BACKGROUND	129	139	O
:	139	140	O
Inflammation	141	153	O
followed	154	162	O
by	163	165	O
fibrosis	166	174	O
is	175	177	O
a	178	179	O
component	180	189	O
of	190	192	O
islet	193	198	B-Multi-tissue_structure
dysfunction	199	210	O
in	211	213	O
both	214	218	O
rodent	219	225	O
and	226	229	O
human	230	235	B-Organism
type	236	240	O
2	241	242	O
diabetes	243	251	O
.	251	252	O

Because	253	260	O
islet	261	266	B-Multi-tissue_structure
inflammation	267	279	O
may	280	283	O
originate	284	293	O
from	294	298	O
endothelial	299	310	B-Cell
cells	311	316	I-Cell
,	316	317	O
we	318	320	O
assessed	321	329	O
the	330	333	O
expression	334	344	O
of	345	347	O
selected	348	356	O
genes	357	362	O
involved	363	371	O
in	372	374	O
endothelial	375	386	B-Cell
cell	387	391	I-Cell
activation	392	402	O
in	403	405	O
islets	406	412	B-Multi-tissue_structure
from	413	417	O
a	418	419	O
spontaneous	420	431	O
model	432	437	O
of	438	440	O
type	441	445	O
2	446	447	O
diabetes	448	456	O
,	456	457	O
the	458	461	O
Goto	462	466	B-Organism
-	466	467	I-Organism
Kakizaki	467	475	I-Organism
(	476	477	I-Organism
GK	477	479	I-Organism
)	479	480	I-Organism
rat	481	484	I-Organism
.	484	485	O

We	486	488	O
also	489	493	O
examined	494	502	O
islet	503	508	B-Tissue
endotheliuml	509	521	I-Tissue
/	521	522	O
oxidative	522	531	O
stress	532	538	O
(	539	540	O
OS	540	542	O
)	542	543	O
/	543	544	O
inflammation	544	556	O
-	556	557	O
related	557	564	O
gene	565	569	O
expression	570	580	O
,	580	581	O
islet	582	587	B-Multi-tissue_structure
vascularization	588	603	O
and	604	607	O
fibrosis	608	616	O
after	617	622	O
treatment	623	632	O
with	633	637	O
the	638	641	O
interleukin	642	653	B-Drug_or_compound
-	653	654	I-Drug_or_compound
1	654	655	I-Drug_or_compound
(	656	657	I-Drug_or_compound
IL	657	659	I-Drug_or_compound
-	659	660	I-Drug_or_compound
1	660	661	I-Drug_or_compound
)	661	662	I-Drug_or_compound
receptor	663	671	I-Drug_or_compound
antagonist	672	682	I-Drug_or_compound
(	683	684	O
IL	684	686	B-Drug_or_compound
-	686	687	I-Drug_or_compound
1Ra	687	690	I-Drug_or_compound
)	690	691	O
.	691	692	O

METHODOLOGY	693	704	O
/	704	705	O
PRINCIPAL	705	714	O
FINDINGS	715	723	O
:	723	724	O
Gene	725	729	O
expression	730	740	O
was	741	744	O
analyzed	745	753	O
by	754	756	O
quantitative	757	769	O
RT	770	772	O
-	772	773	O
PCR	773	776	O
on	777	779	O
islets	780	786	B-Multi-tissue_structure
isolated	787	795	O
from	796	800	O
10	801	803	O
-	803	804	O
week	804	808	O
-	808	809	O
old	809	812	O
diabetic	813	821	O
GK	822	824	B-Organism
and	825	828	O
control	829	836	O
Wistar	837	843	B-Organism
rats	844	848	I-Organism
.	848	849	O

Furthermore	850	861	O
,	861	862	O
GK	863	865	B-Organism
rats	866	870	I-Organism
were	871	875	O
treated	876	883	O
s	884	885	O
.	885	886	O
c	886	887	O
twice	888	893	O
daily	894	899	O
with	900	904	O
IL	905	907	B-Drug_or_compound
-	907	908	I-Drug_or_compound
1Ra	908	911	I-Drug_or_compound
(	912	913	O
Kineret	913	920	B-Drug_or_compound
,	920	921	O
Amgen	922	927	O
,	927	928	O
100	929	932	O
mg	933	935	O
/	935	936	O
kg	936	938	O
/	938	939	O
day	939	942	O
)	942	943	O
or	944	946	O
saline	947	953	B-Drug_or_compound
,	953	954	O
from	955	959	O
4	960	961	O
weeks	962	967	O
of	968	970	O
age	971	974	O
onwards	975	982	O
(	983	984	O
onset	984	989	O
of	990	992	O
diabetes	993	1001	O
)	1001	1002	O
.	1002	1003	O

Four	1004	1008	O
weeks	1009	1014	O
later	1015	1020	O
,	1020	1021	O
islet	1022	1027	B-Multi-tissue_structure
gene	1028	1032	O
analysis	1033	1041	O
and	1042	1045	O
pancreas	1046	1054	B-Organ
immunochemistry	1055	1070	O
were	1071	1075	O
performed	1076	1085	O
.	1085	1086	O

Thirty	1087	1093	O
-	1093	1094	O
two	1094	1097	O
genes	1098	1103	O
were	1104	1108	O
selected	1109	1117	O
encoding	1118	1126	O
molecules	1127	1136	O
involved	1137	1145	O
in	1146	1148	O
endothelial	1149	1160	B-Cell
cell	1161	1165	I-Cell
activation	1166	1176	O
,	1176	1177	O
particularly	1178	1190	O
fibrinolysis	1191	1203	O
,	1203	1204	O
vascular	1205	1213	O
tone	1214	1218	O
,	1218	1219	O
OS	1220	1222	O
,	1222	1223	O
angiogenesis	1224	1236	O
and	1237	1240	O
also	1241	1245	O
inflammation	1246	1258	O
.	1258	1259	O

All	1260	1263	O
genes	1264	1269	O
except	1270	1276	O
those	1277	1282	O
encoding	1283	1291	O
angiotensinogen	1292	1307	B-Gene_or_gene_product
and	1308	1311	O
epoxide	1312	1319	B-Gene_or_gene_product
hydrolase	1320	1329	I-Gene_or_gene_product
(	1330	1331	O
that	1331	1335	O
were	1336	1340	O
decreased	1341	1350	O
)	1350	1351	O
,	1351	1352	O
and	1353	1356	O
12	1357	1359	B-Gene_or_gene_product
-	1359	1360	I-Gene_or_gene_product
lipoxygenase	1360	1372	I-Gene_or_gene_product
and	1373	1376	O
vascular	1377	1385	B-Gene_or_gene_product
endothelial	1386	1397	I-Gene_or_gene_product
growth	1398	1404	I-Gene_or_gene_product
factor	1405	1411	I-Gene_or_gene_product
(	1412	1413	O
that	1413	1417	O
showed	1418	1424	O
no	1425	1427	O
change	1428	1434	O
)	1434	1435	O
,	1435	1436	O
were	1437	1441	O
significantly	1442	1455	O
up	1456	1458	O
-	1458	1459	O
regulated	1459	1468	O
in	1469	1471	O
GK	1472	1474	B-Organism
islets	1475	1481	B-Multi-tissue_structure
.	1481	1482	O

After	1483	1488	O
IL	1489	1491	B-Drug_or_compound
-	1491	1492	I-Drug_or_compound
1Ra	1492	1495	I-Drug_or_compound
treatment	1496	1505	O
of	1506	1508	O
GK	1509	1511	B-Organism
rats	1512	1516	I-Organism
in	1517	1519	O
vivo	1520	1524	O
,	1524	1525	O
most	1526	1530	O
selected	1531	1539	O
genes	1540	1545	O
implied	1546	1553	O
in	1554	1556	O
endothelium	1557	1568	B-Tissue
/	1568	1569	O
OS	1569	1571	O
/	1571	1572	O
immune	1572	1578	B-Cell
cells	1579	1584	I-Cell
/	1584	1585	O
fibrosis	1585	1593	O
were	1594	1598	O
significantly	1599	1612	O
down	1613	1617	O
-	1617	1618	O
regulated	1618	1627	O
.	1627	1628	O

IL	1629	1631	B-Drug_or_compound
-	1631	1632	I-Drug_or_compound
1Ra	1632	1635	I-Drug_or_compound
also	1636	1640	O
improved	1641	1649	O
islet	1650	1655	B-Multi-tissue_structure
vascularization	1656	1671	O
,	1671	1672	O
reduced	1673	1680	O
fibrosis	1681	1689	O
and	1690	1693	O
ameliorated	1694	1705	O
glycemia	1706	1714	O
.	1714	1715	O

CONCLUSIONS	1716	1727	O
/	1727	1728	O
SIGNIFICANCE	1728	1740	O
:	1740	1741	O
GK	1742	1744	B-Organism
rat	1745	1748	I-Organism
islets	1749	1755	B-Multi-tissue_structure
have	1756	1760	O
increased	1761	1770	O
mRNA	1771	1775	O
expression	1776	1786	O
of	1787	1789	O
markers	1790	1797	O
of	1798	1800	O
early	1801	1806	O
islet	1807	1812	B-Cell
endothelial	1813	1824	I-Cell
cell	1825	1829	I-Cell
activation	1830	1840	O
,	1840	1841	O
possibly	1842	1850	O
triggered	1851	1860	O
by	1861	1863	O
several	1864	1871	O
metabolic	1872	1881	O
factors	1882	1889	O
,	1889	1890	O
and	1891	1894	O
also	1895	1899	O
some	1900	1904	O
defense	1905	1912	O
mechanisms	1913	1923	O
.	1923	1924	O

The	1925	1928	O
beneficial	1929	1939	O
effect	1940	1946	O
of	1947	1949	O
IL	1950	1952	B-Drug_or_compound
-	1952	1953	I-Drug_or_compound
1Ra	1953	1956	I-Drug_or_compound
on	1957	1959	O
most	1960	1964	O
islet	1965	1970	B-Cell
endothelial	1971	1982	I-Cell
/	1982	1983	O
OS	1983	1985	O
/	1985	1986	O
immune	1986	1992	B-Cell
cells	1993	1998	I-Cell
/	1998	1999	O
fibrosis	1999	2007	O
parameters	2008	2018	O
analyzed	2019	2027	O
highlights	2028	2038	O
a	2039	2040	O
major	2041	2046	O
endothelial	2047	2058	O
-	2058	2059	O
related	2059	2066	O
role	2067	2071	O
for	2072	2075	O
IL	2076	2078	B-Gene_or_gene_product
-	2078	2079	I-Gene_or_gene_product
1	2079	2080	I-Gene_or_gene_product
in	2081	2083	O
GK	2084	2086	B-Organism
islet	2087	2092	B-Multi-tissue_structure
alterations	2093	2104	O
.	2104	2105	O

Thus	2106	2110	O
,	2110	2111	O
metabolically	2112	2125	O
-	2125	2126	O
altered	2126	2133	O
islet	2134	2139	B-Tissue
endothelium	2140	2151	I-Tissue
might	2152	2157	O
affect	2158	2164	O
the	2165	2168	O
beta	2169	2173	B-Cell
-	2173	2174	I-Cell
cell	2174	2178	I-Cell
microenvironment	2179	2195	O
and	2196	2199	O
contribute	2200	2210	O
to	2211	2213	O
progressive	2214	2225	O
type	2226	2230	O
2	2231	2232	O
diabetic	2233	2241	O
beta	2242	2246	B-Cell
-	2246	2247	I-Cell
cell	2247	2251	I-Cell
dysfunction	2252	2263	O
in	2264	2266	O
GK	2267	2269	B-Organism
rats	2270	2274	I-Organism
.	2274	2275	O

Counteracting	2276	2289	O
islet	2290	2295	B-Cell
endothelial	2296	2307	I-Cell
cell	2308	2312	I-Cell
inflammation	2313	2325	O
might	2326	2331	O
be	2332	2334	O
one	2335	2338	O
way	2339	2342	O
to	2343	2345	O
ameliorate	2346	2356	O
/	2356	2357	O
prevent	2357	2364	O
beta	2365	2369	B-Cell
-	2369	2370	I-Cell
cell	2370	2374	I-Cell
dysfunction	2375	2386	O
in	2387	2389	O
type	2390	2394	O
2	2395	2396	O
diabetes	2397	2405	O
.	2405	2406	O

